Effect of ligand binding on human D-amino acid oxidase: Implications for the development of new drugs for schizophrenia treatment by Caldinelli L. et al.
Effect of ligand binding on human
D-amino acid oxidase: Implications
for the development of new drugs
for schizophrenia treatment
Laura Caldinelli,1,2 Gianluca Molla,1,2 Luisa Bracci,3 Barbara Lelli,3 Silvia Pileri,3
Pamela Cappelletti,1,2 Silvia Sacchi,1,2 and Loredano Pollegioni1,2*
1Dipartimento di Biotecnologie e Scienze Molecolari, Universita` degli studi dell’Insubria, via J.H. Dunant 3, 21100 Varese
2Centro Interuniversitario di Ricerca in Biotecnologie Proteiche ‘‘The Protein Factory,’’ Politecnico di Milano and Universita`
degli studi dell’Insubria, Italy
3Department of Molecular Biology, University of Siena, Siena 53100, Italy
Received 25 February 2010; Revised 17 May 2010; Accepted 17 May 2010
DOI: 10.1002/pro.429
Published online 2 June 2010 proteinscience.org
Abstract: In human brain the flavoprotein D-amino acid oxidase (hDAAO) is responsible for the
degradation of the neuromodulator D-serine, an important effector of NMDA-receptor mediated
neurotransmission. Experimental evidence supports the concept that D-serine concentration
increase by hDAAO inhibition may represent a valuable therapeutic approach to improve the
symptoms in schizophrenia patients. This study investigated the effects on hDAAO conformation
and stability of the substrate D-serine (or of the pseudo-substrate trifluoro-D-alanine), the FAD
cofactor, and two inhibitors (benzoate, a classical substrate-competitive inhibitor and the drug
chlorpromazine (CPZ), which competes with the cofactor). We demonstrated that all these
compounds do not alter the interaction of hDAAO with its physiological partner pLG72. The ligands
used affect the tertiary structure of hDAAO differently: benzoate or trifluoro-D-alanine binding
increases the amount of the holoenzyme form in solution and stabilizes the flavoprotein, while CPZ
binding favors a protein conformation resembling that of the apoprotein, which is more sensitive to
degradation. Interestingly, the apoprotein form of hDAAO binds the substrate D-serine: this
interaction increases FAD binding thus increasing the amount of active holoenzyme in solution.
Benzoate and CPZ similarly modify the short-term cellular D-serine concentration but affect the
cellular concentration of hDAAO differently. In conclusion, the different alteration of hDAAO
conformation and stability by the ligands used represents a further parameter to take into
consideration during the development of new drugs to cope schizophrenia.
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Introduction
D-Amino acid oxidase (DAAO, EC 1.4.3.3) is a FAD-
dependent flavoenzyme that catalyzes the stereospe-
cific oxidative deamination of D-amino acids to the
corresponding a-keto acids, hydrogen peroxide, and
ammonia.1 Experimental evidence shows that, in
brain, this flavoenzyme degrades the gliotransmitter
D-serine, the only neutral D-amino acid present at
significant concentration in this tissue: D-serine
binds the glycine modulatory site on the NMDA
Abbreviations: Bz, benzoate; CPZ, chlorpromazine; CF3-D-Ala,
trifluoro-D-alanine; hDAAO, human D-amino acid oxidase (EC
1.4.3.3); NLS, N-lauroylsarcosine; pkDAAO, pig kidney D-amino
acid oxidase; SPR, surface plasmon resonance; Tm, melting
temperature.
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receptor, allowing the activation of the receptor by
glutamate, for a review see Refs. 2 and 3. The gluta-
matergic hypothesis of schizophrenia, the most
severe human psychiatric disorder, is based on hypo-
function of NMDA receptors. This theory is sup-
ported by observations that glycine abolishes the
psychotomimetic effect of ketamine and improves
neuroleptic therapy and that the most interesting
susceptibility genes for schizophrenia act on gluta-
matergic transmission mediated by NMDA recep-
tors.4,5 Among these, the genes encoding for human
DAAO (hDAAO) and its putative binding partner
pLG72 have been linked to schizophrenia suscepti-
bility through genetic analysis of different human
populations.6 We recently demonstrated that in vitro
hDAAO specifically interacts with pLG72, yielding a
 200-kDa complex constituted by 2 hDAAO homo-
dimers and 2 pLG72 monomers.7–9 This interaction
results in a time-dependent loss of hDAAO activity
which is mainly due to alteration of the tertiary
structure of hDAAO. Furthermore, we confirmed
in vivo the hDAAO-pLG72 interaction and demon-
strated that the cellular concentration of D-serine
decreases in U87 glioblastoma cells transfected with
a plasmid encoding for hDAAO but is not modified
in those simultaneously transfected with cDNAs
encoding both pLG72 and hDAAO.9 Therefore, we
proposed a molecular mechanism by which hDAAO
and pLG72 are involved in schizophrenia susceptibil-
ity: an anomalous increase in hDAAO activity (e.g.,
related to pLG72 hypoexpression) will result in a
decrease in the synaptic concentration of D-serine,
thus causing hypofunctionality of NMDA receptor-
mediated neurotransmission. Importantly, and in
agreement with the aforementioned model, hDAAO
is now considered the target for a new class of drugs
(hDAAO inhibitors) to treat schizophrenia.10–13
Human DAAO shows the main properties of the
dehydrogenase-oxidase class of flavoproteins and
shares a low turnover number and a ternary com-
plex (sequential) kinetic mechanism with pig kidney
DAAO (pkDAAO, 85% sequence identity).7 Indeed,
this human flavoenzyme can be distinguished from
the other known DAAOs because it is a stable homo-
dimer even in the apoprotein form, because the bind-
ing of the FAD cofactor is the weakest among the
known DAAOs (Kd value is in the micromolar
range)1,7 and because it specifically interacts with
pLG72 (which is expressed on primates only).6 These
features raise a question concerning the actual
in vivo activity of hDAAO: based on the weak cofac-
tor binding (FAD concentration in brain is estimated
to be 5 lM)14 hDAAO might be largely present in
the inactive apoprotein form. It is noteworthy that a
20-fold tighter interaction between the FAD cofactor
and the protein moiety is observed in the presence
of the competitive inhibitor benzoate.7 Furthermore,
we have recently shown that the apoprotein of
hDAAO can be distinguished from the corresponding
holoenzyme form by the ‘‘more open’’ tertiary struc-
ture and larger exposure of hydrophobic surfaces; it
is also a slightly more sensitive to denaturation by
urea or temperature.15
In this work we analyze the consequences of
ligand binding on conformation and stability of
hDAAO alone and in complex with pLG72. To reach
this goal, the substrate D-serine or the pseudo-sub-
strate trifluoro-D-alanine (CF3-D-Ala), benzoate (the
most studied substrate–competitive inhibitor of
hDAAO, Kd ¼ 7 lM),1,9,16 and the drug chlorproma-
zine (CPZ) were employed. The aliphatic phenothia-
zine CPZ is a dopamine D2 receptor antagonist that
was introduced in the treatment of schizophrenia in
the early 1950s; it also acts as a FAD-competitive in-
hibitor of hDAAO (Kd ¼ 5 lM).9,17 We here demon-
strate that the different ligands affect the conforma-
tion and stability of the holoenzyme and apoprotein
forms of the human flavoenzyme as well as the cellu-
lar concentration of hDAAO differently. We also pro-
vide evidence that these ligands do not alter the inter-
action between hDAAO and pLG72 and that affect the
time course of cellular D-serine concentration similarly.
Results
Effect of ligand binding on the conformation
of hDAAO
Spectral properties (and quaternary
structure). Because of the weak interaction with
the FAD cofactor (Kd ¼ 8 6 2 lM), the recombinant
hDAAO exists in solution as an equilibrium of holo-
and apoprotein forms (at 1 mg protein/mL the solu-
tion contains similar amounts of the two protein spe-
cies). The holoenzyme shows the typical absorbance
spectrum of the FAD-containing flavoproteins, with
maxima at 454, 372, and 278 nm.7 The interaction of
hDAAO with the competitive inhibitor benzoate
results in a typical perturbation of the flavin absorb-
ance spectrum (formation of a shoulder at 500 nm)
from which a Kd of 7 6 2 lM was estimated.
7 Inter-
estingly, in the presence of a saturating concentra-
tion of benzoate the Kd for FAD binding decreases to
0.3 6 0.1 lM and, therefore, a 1-mg hDAAO/mL
solution contains  90% of the corresponding holo-
enzyme form. We also demonstrated that CPZ binds
to the apoprotein form of hDAAO with an affinity
similar to that estimated for FAD.9 Furthermore,
and differently to that observed for FAD binding,
the presence of benzoate does not modify the Kd for
CPZ binding to hDAAO apoprotein.
The observation that benzoate increases the
binding of FAD to hDAAO apoprotein9 suggested
that a similar effect might also be given by the phys-
iological substrate D-serine. This hypothesis cannot
be directly verified because the substrate reduces
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the flavin cofactor generating the enzyme-product
complex and altering the enzyme spectral properties.
Similarly, L-serine cannot be used since it is neither
substrate or inhibitor of hDAAO. CF3-D-Ala is a
pseudo-substrate of DAAO that was previously used
to deep insight the mode of substrate binding in the
yeast enzyme:18 it possesses all the structural and
steric requirements to be a substrate of DAAO but
dehydrogenation is not feasible because of the induc-
tive effect due to the ACF3 side chain. In fact, the
addition of CF3-D-Ala under anaerobic conditions
does not convert the oxidized hDAAO into the
reduced enzyme form, as instead observed using a
classical substrate such as D-alanine.1,7,9 CF3-D-Ala
acts as competitive inhibitor of hDAAO: the Ki value
(3.0 6 0.5 mM) is close to the Km,app value deter-
mined for D-serine (7.5 mM).7 A further demonstra-
tion of CF3-D-Ala binding to hDAAO was achieved
measuring the Kd for FAD binding in the presence of
the pseudo-substrate: following the change in protein
fluorescence a Kd ¼ 0.5 6 0.1 lM was determined, a
value in good agreement with that observed for the
hDAAO-benzoate complex (see previous).
Tryptophan fluorescence (following excitation at
280 nm) shows an emission maximum at 332 nm for
the holoenzyme and at 338 nm for the apoprotein of
hDAAO; the emission intensity being fivefold higher
in the apo- than in the holoprotein, which indicates
that the relevance of quenching interactions between
tryptophans and nearby side chains is different in
the two protein forms.15 The addition of 0.1 mM ben-
zoate yields a significant quenching of hDAAO holo-
enzyme fluorescence [the emission at 338 nm drops
from 210 to 165 a.u., Fig. 1(A)], while the change is
Figure 1. Effect of adding benzoate, CF3-D-Ala or CPZ on the spectral properties of hDAAO holoenzyme. (A) Comparison of
protein fluorescence (excitation at 280 nm) of 2.5 lM (¼ 0.1 mg protein/mL) hDAAO before ( , in the absence and , in
the presence of 40 lM FAD) and after adding 0.1 mM benzoate ( , in the absence and , in the presence of 40 lM
FAD). (B) Comparison of protein fluorescence of hDAAO before and after adding 30 mM CF3-D-Ala (conditions as in panel A).
(C) Comparison of protein fluorescence of hDAAO before and after adding 0.1 mM CPZ (conditions as in panel A). (D) Effect
of benzoate addition on the near-UV CD spectrum of hDAAO (10 lM ¼ 0.4 mg protein/mL): (1, —) no benzoate; (2, )
4.8 lM benzoate; (3, ) 48 lM benzoate. Inset: change in CD signal at 275 nm at increasing benzoate concentrations.
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marginal in the presence of 40 lM free FAD. Most
significant alterations in protein fluorescence are
observed using CF3-D-Ala: a 160 a.u. decrease in flu-
orescence intensity is observed at saturating concen-
tration of the pseudo-substrate (Kd ¼ 3.9 6 0.1 mM),
while FAD fails to give additional modification [Fig.
1(B)]. These results indicate that the change in pro-
tein fluorescence following benzoate or CF3-D-Ala
binding to hDAAO is related to the acquisition of a
protein conformation resembling that of the holo-
enzyme form (while at 0.1 mg hDAAO/mL concentra-
tion and in the absence of a ligand the solution con-
tains 80% of the corresponding apoprotein form).
Under the same experimental conditions, the addition
of 0.1 mM CPZ yields a quenching of protein fluores-
cence of hDAAO similar to that observed following
benzoate binding when the holoenzyme is used [Fig.
1(C)]. Indeed, the addition of 0.1 mM CPZ in the
presence of 40 lM FAD alters the emission spectrum
more significantly than when benzoate is used, thus
pointing to a different alteration of hDAAO conforma-
tion as compared to adding benzoate or CF3-D-Ala.
A larger change in protein fluorescence intensity
(from 295 up to 95 a.u.) is apparent using the apo-
protein form of hDAAO following D-serine or CF3-D-
Ala addition (Kd ¼ 3.0 6 0.3 and 4.6 6 0.2 mM,
respectively): this also demonstrates that the apo-
protein is competent in substrate binding. A similar
fluorescence change is apparent adding 0.1 mM CPZ
while no modification is observed using benzoate.
The far-UV CD spectra of apo- and holoprotein
of hDAAO are identical, revealing a similar amount
of secondary structure (not shown). In agreement
with this observation, adding 0.1 mM FAD, benzo-
ate, CF3-D-Ala or CPZ does not modify the far-UV
CD spectrum of the protein. Differences are instead
apparent in the near-UV CD spectra of the apo- and
holoprotein forms, further indicating a slight altera-
tion of the tertiary structure after cofactor binding.15
The near-UV CD features of hDAAO holoenzyme are
to some extent modified by adding benzoate and
CF3-D-Ala. At increasing ligand concentrations an
higher intensity in the  270-nm signal is apparent,
from which Kd values of 9.5 6 0.7 lM and 3.1 6 0.6
mM are determined for benzoate and CF3-D-Ala,
respectively [see Fig. 1(D) for benzoate]. Indeed, the
addition of CPZ decreases the CD signal at 270 nm,
a change that is more evident in the presence of 40
lM FAD and that is not observed using the apopro-
tein form of hDAAO (not shown). These results
reveal a different alteration of hDAAO tertiary
structure following the binding of the ligands used.
We previously reported that both the holo- and
apoprotein forms of hDAAO elute in size-exclusion
chromatography as a single peak corresponding to an
80-kDa homodimer in the 0.1- to 10-mg protein/mL
concentration range.7 Under the same conditions, the
addition of 40 lM FAD in the elution buffer does not
modify the elution volume of either the holo- or apo-
protein forms of hDAAO or alter the presence of 0.1
mM benzoate, CF3-D-Ala or CPZ (not shown).
Limited proteolysis studies. Limited proteolysis
of proteins in a native-like state is a strong tool to
test changes in the higher-order structure in
response to ligand binding.19 SDS-PAGE Analysis
during limited proteolysis experiments of the
hDAAO apoprotein form (using 10% (w/w) trypsin
and at 25C) clearly shows that the 40-kDa band
corresponding to the intact protein is fully degraded
in a monophasic process in 10 minutes (kobs1 ¼
0.27 min1, Fig. 2). On the other hand, proteolysis of
the holoenzyme (in the absence of exogenous FAD) is
a biphasic and slower process: first there is a rapid
phase that accounts for the degradation of 68% of
the protein (reasonably corresponding to the amount
of apoprotein in solution, kobs1 ¼ 0.30 min1) which
is followed by a slow phase (kobs2 ¼ 7  103 min1,
Fig. 2 and Table I). Adding 0.1 mM FAD largely pro-
tects hDAAO from trypsin cleavage: more than 75%
of the intact enzyme is still present after 30 min of
incubation (Fig. 2). Indeed, the apoprotein, too, is
largely protected from proteolysis by previous incu-
bation for 5 minutes with the cofactor: the sensitiv-
ity of the reconstituted holoprotein to trypsin resem-
bles that of the native hDAAO holoenzyme (Table I).
The presence of 1 mM benzoate or of 30 mM
CF3-D-Ala increases the amount of hDAAO that is
resistant to protease (Fig. 2). In contrast, the addi-
tion of 0.1 mM CPZ increases the sensitivity of
hDAAO holoenzyme to trypsinolysis: a 10-fold
increase in the rate constant for the second phase of
degradation is observed (kobs2 ¼ 6  102 min1,
Fig. 2). However, adding CPZ, benzoate or CF3-D-Ala
to the hDAAO apoprotein does not modify the time
course of proteolysis (Table I).
Taken together, data from limited proteolysis
experiments indicate that the amplitude of the
observed first phase of proteolysis of the holo-
enzyme correlates with the amount of apoprotein
present in solution; the second phase is related to
the slow FAD dissociation from the remaining holo-
enzyme form. The ligands benzoate and CF3-D-Ala
increase the amount of holoenzyme species in solu-
tion (thus decreasing the amplitude of the first
phase) and prevent FAD dissociation from the
remaining holoenzyme form (thus slowing down/
abolishing the second phase). In contrast, binding
of CPZ increases the susceptibility of hDAAO holo-
enzyme by accelerating the second phase of proteol-
ysis (see Table I).
Effect of ligand binding on the thermal
stability of hDAAO
A comparison of the temperature sensitivity of spe-
cific structural features of hDAAO showed higher
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midpoint transition temperatures for the holo- than
for the apoprotein form.15 We now performed tem-
perature ramp experiments in the presence of the
ligands by following the change in protein fluores-
cence (Table II). The addition of 0.1 mM benzoate or
30 mM CF3-D-Ala increases the Tm value of the holo-
enzyme form of hDAAO (DTm  5C), while the pres-
ence of 0.1 mM CPZ destabilizes the same enzyme
form. In contrast, the stability of the apoprotein of
hDAAO is not altered by benzoate (there is no evi-
dence of benzoate binding to hDAAO apoprotein),
while CPZ and CF3-D-Ala binding moderately stabil-
izes this protein form (DTm  2C).
Effect of benzoate (and CF3-D-Ala) on the
FAD-binding process to hDAAO apoprotein
By using the time courses of flavin and protein fluores-
cence and activity recovery, we recently demonstrated15
that the overall hDAAO holoenzyme reconstitution pro-
cess starting from apoprotein and free FAD can be
described by the series of steps reported in Eq. (1):
APOþ FAD ¢k1
k1
Holo !k2 Holo (1)
FAD binding to the apoprotein moiety is a reversible
process which yields a catalytically competent Holo*
form (steps k1/k-1); the k2 rate constant (¼ 0.0034 6
0.0002 s1) pertains to a sequential rearrangement of
the reconstituted holoenzyme (and it is only apparent
following the protein fluorescence). We now analyzed
the kinetics of reconstitution of the hDAAO apopro-
tein-FAD complex under the same experimental con-
ditions (pseudo-first order conditions, at 15C) and
in the presence of 1 mM benzoate (in the presence of
benzoate the recovery of enzyme activity cannot be
used to test holoenzyme reconstitution). The time
course of flavin fluorescence change is monophasic
and depends on apoprotein concentration: in the ab-
sence of benzoate, the amplitude of the fluorescence
change increases with the amount of apoprotein
used and corresponds to the amount of reconstituted
holoenzyme. In contrast, the amplitude of fluores-
cence change is always maximal when 1 mM benzo-
ate is present [Fig. 3(A)], thus indicating that a
large part of the holoprotein is reconstituted in the
presence of the ligand at all protein concentrations
used. The observed first-order rate constant for the
change in flavin fluorescence shows a linear depend-
ence on the apoprotein concentration in both the ab-
sence and presence of the ligand: the only difference
is that a clear y-intercept is manifest in the former
[Fig. 3(B)]. Such a behavior is indicative of a reversi-
ble second-order process, with k1 rate constants of
0.7 and 1.0 mM1s1 and k-1 values of 0.0074 and 
0.0005 s1 in the absence and in the presence of ben-
zoate, respectively. The Kd value for FAD binding to
hDAAO apoprotein estimated from the kinetic data
is 10 and 0.5 lM in the absence and in the presence
of benzoate, respectively, which is in good agreement
with the values obtained from static titrations.7
Noteworthy, the time course of fluorescence change
observed using a saturating concentration of CF3-D-
Figure 2. Time course of trypsin digestion of different hDAAO forms (10 lM ¼ 0.4 mg protein/mL) with 10% (w/w) trypsin at
25C in 20 mM Tris-HCl pH 8.5, 150 mM NaCl, 5% glycerol, 0.06% NLS, and 5 mM 2-mercaptoethanol. Panel A) SDS-PAGE
Analysis of samples at different times: (lane Ctrl) control before adding trypsin; (lane 1) immediately after adding trypsin (30 s);
(lanes 2–4) 2, 5, and 30 min after adding trypsin. APO ¼ Apoprotein; HOLO ¼ holoenzyme; HOLOþBz ¼ holoenzyme to
which 1 mM benzoate was added; HOLOþCPZ ¼ holoenzyme to which 0.1 mM CPZ was added. B) Time course of the
intensity of the 40-kDa band (corresponding to the intact hDAAO monomer) as determined by densitometric analysis of gels
such as those reported in panel A. HOLOþFAD is the sample obtained following the addition of 100 lM free FAD to the
hDAAO holoenzyme. The intensity of the 40-kDa band of the sample before adding trypsin (sample in lane Ctrl, panel A) is
indicated as 100%. Bars indicate S.E. as determined for at least three independent experiments.
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Ala is identical to that determined using benzoate as
hDAAO ligand (not shown).
Effect of ligand binding on the hDAAO-pLG72
complex formation
hDAAO binds pLG72 yielding an 200-kDa complex
constituted by 2 hDAAO homodimers and 2 pLG72
monomers.9 The presence of 40 lM free FAD and 0.1
mM CPZ or benzoate in the elution buffer does not
affect the amount of protein complex formed as
judged by size exclusion chromatography and meas-
uring the area of the corresponding peak at 12.8
mL.9 A comparable result is also apparent using the
apoprotein form of hDAAO (and in the absence of
free FAD in the elution buffer, data not shown). In
both cases a saturation in the peak’s area corre-
sponding to the hDAAO-pLG72 complex is attained
at a 2:1 molar ratio, as previously assessed in the
absence of CPZ.9
Real-time interaction analyses between hDAAO
and pLG72 as well as between its different ligands
were performed by SPR method. Both pLG72 and
hDAAO were individually immobilized by standard
amine coupling chemistry on a CM5 sensor chip.
The signals describing the interaction of a ligand-
free hDAAO solution flushed over a sensor with im-
mobilized pLG72 in the absence and in the presence
of 40 lM FAD [Fig. 4(A,B)] are threefold higher for
the holoenzyme than for the apoprotein form of
hDAAO. The sensorgrams were analyzed by means
of Biacore 1.1.1 software and showed similar appa-
rent affinities (Kd values were 5.3 vs. 3.1  107M
with and without free FAD, respectively). The appa-
rent affinity is higher than that determined previ-
ously using a different buffer composition (Kd ¼ 8
lM).9 Indeed, no signal was observed using control
proteins (human serum albumin or acylase), thus
confirming the specificity of recognition. Compara-
tive analyses of sensorgrams were carried out using
hDAAO-immobilized sensors and flushing different
concentrations of pLG72 with or without 20 lM free
FAD [Fig. 4(C,D)]. Under these conditions, the ka
association rate constants are higher than with im-
mobilized pLG72 and the traces are not affected by
the presence of FAD [Fig. 4(C,D); Kd value is 0.8 6
0.1  107M].
Under similar experimental conditions, the ka
and kd values for pLG72 binding and dissociation to
immobilized hDAAO are unchanged in the presence
of 20 lM CPZ, of 35 lM benzoate (with or without
40 lM free FAD), or of 50 mM D-serine (not shown).
Indeed, from these experimental time courses bind-
ing data for the small ligand interaction to hDAAO
were determined.20 The corresponding values are
reported in Table III and correspond well with Kd
values previously determined by static titration or
from Michaelis-Menten kinetics (for the substrate
D-serine) for hDAAO alone. The most significantT
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discrepancy ( 40-fold) is observed for the binding of
the FAD cofactor, for which the interaction with
hDAAO apoprotein is known to be affected by the ex-
perimental conditions used but not by pLG72 bind-
ing.20 Otherwise, the latter result might also arises
from slight alterations in hDAAO conformation/
dynamics following the immobilization procedure.
Limited proteolysis studies
Limited proteolysis experiments were used to probe
ligand-induced conformational changes in the
hDAAO-pLG72 complex. At first the effect of
increasing amounts of pLG72 on the time course of
degradation of the 40-kDa band of hDAAO (corre-
sponding to the intact monomer) was investigated.
As shown in Figure 5, the presence of a stoichiomet-
ric amount of pLG72 increases the rate constant for
the second phase of holoenzyme degradation; fur-
thermore, the destabilization of hDAAO was most
evident when a twofold excess of pLG72 was added
(Table I). On the other hand, the time course of pro-
teolysis of the apoprotein form is not affected by the
addition of pLG72 (cf. Figs. 2 and 5).
Concerning the effect of small ligands on the
trypsin susceptibility of the hDAAO-pLG72 complex
(obtained mixing stoichiometric amounts of hDAAO
and pLG72) the presence of 0.1 mM free FAD halves
the amount of protein degraded in the first (rapid)
phase and slows down the second phase of proteoly-
sis of the hDAAO holoenzyme (this latter phase is
absent when pLG72 is missing, see Table I). The
addition of 0.1 mM CPZ produces a hDAAO-pLG72
complex which is fully sensitive to proteolysis, simi-
larly to that observed for the free apoprotein (Fig. 5
and Table I). However, the holoenzyme is partially
protected from degradation in the presence of 0.1
mM benzoate or 30 mM CF3-D-Ala ( 45% of the
enzyme is resistant to proteolysis, Figure 5, analo-
gously to that observed in the absence of pLG72).
Taken together, these results suggest that pLG72
binding destabilizes the holoenzyme form of hDAAO,
an effect which is counteracted by FAD, CF3-D-Ala
and benzoate binding.
Effect of benzoate and CPZ on cellular D-serine
and hDAAO concentrations
To investigate the effect of hDAAO ligands at the cel-
lular level, we produced stably transfected U87
human glioblastoma cells expressing EGFP-hDAAO.9
The fusion of the GFP protein at the N-terminus of
hDAAO does not alter the main properties of the fla-
vooxidase. The recombinant EGFP-hDAAO is active
Figure 3. Effect of benzoate on the kinetics of hDAAO apoprotein reconstitution with FAD. (A) Overlay of time course of flavin
fluorescence quenching in the absence (n) and in the presence (l) of 1 mM sodium benzoate after mixing a 10-fold excess
of apoprotein (0.6 lM FAD to which 6 lM apoprotein solution was added) at pH 8.3 and 15C. The fits through the data
points are obtained according to a single exponential decay equation. (B) Effect of apoprotein concentration on the observed
first-order rate constants (kobs) of the reaction of FAD with hDAAO apoprotein. The values of kobs were determined from
experiments such as those reported in panel A.
Table II. Effect of Ligand Binding on the Tm Values for hDAAO Unfolding as Determined by Protein Fluorescence
Tm (
C)
Apoprotein Holoenzyme
þBz þCF3-D-Ala þCPZ þFAD þBz þBz þFAD þCF3-D-Ala þCF3-D-Ala þFAD þCPZ
50.2
6 1.5
50.1
6 1.7
52.8
6 0.2
52.0
6 1.3
50.1
6 0.2
51.8
6 0.2
55.2
6 0.2
55.4
6 0.2
54.7
6 0.2
55.7
6 0.2
48.0
6 0.7
Fluorescence experiments were performed at an identical heating rate (0.5C/min) in the absence and in the presence of
0.1 mM benzoate, 0.1 mM CPZ, 30 mM CF3-D-Ala, and/or 40 lM FAD. Protein concentration was 0.1 mg/mL. Tm values
were obtained by calculating the first derivative of the spectroscopic signals and are uncorrected for delay effects.15
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(kcat is 2.5 s
1 and Km is 4 mM vs. 3.0 s
1 and 7 mM
for the wild-type on D-serine) and each protein
monomer (69 kDa) interacts with one molecule of
FAD (with a Kd of 7 lM vs. 8 lM as determined for
wild-type hDAAO).7 Furthermore, EGFP-hDAAO
interacts with pLG72 yielding a complex which mo-
lecular mass is about twice that of the native di-
meric enzyme (in agreement with the formation of a
complex constituted by two hDAAO homodimers and
two pLG72 molecules) and which time course of
inactivation strictly resembles that observed using
the native hDAAO.9 U87 Transfected cells were
treated with 10 or 100 lM benzoate (these two con-
centrations yielded similar results) or 10 lM CPZ
and the D- and L-serine concentrations were deter-
mined by HPLC chromatography (these concentra-
tions of hDAAO inhibitors do not affect cell viability
while massive cell death was observed at 100 lM
CPZ). Both compounds yield a statistically signifi-
cant increase in D/(DþL) serine concentration ratio
as compared to untreated controls after 24 hours, a
change that is cleared 48 hours later [Fig. 6(A)]. No
significant differences were observed in the amount
of cellular hDAAO, as determined by means of West-
ern blot analysis and activity assay, with the only
exception being CPZ-treatment after 48 hours [20%
decrease, Fig. 6(B)]. The same experiment was car-
ried out using U87 glioblastoma cells stably produc-
ing EGFP-hDAAO and transiently expressing pLG72.
Under these conditions, CPZ treatment significantly
decreases the amount of active hDAAO while benzo-
ate slightly increases the cellular hDAAO in cotrans-
fected cells [see values at 48 hours in Fig. 6(C)].
These latter results resemble the effects exerted by
Figure 4. Sensorgrams (Biacore analysis) of the interaction between pLG72 and hDAAO. Panels (A,B) Kinetic evaluation of
hDAAO apoprotein and holoenzyme binding to immobilized pLG72. Apo- (panel A) and holoprotein of hDAAO (panel B) diluted
in HBS EPþ buffer at concentration of 1.38, 2.75, and 5.51 lM was injected at a flow rate of 20 lL/min over pLG72
previously immobilized on a CM5 sensor chip. The ‘‘on’’ and ‘‘off’’ rates were calculated with Biacore T100 BIAevaluation
software. An unrelated protein at a concentration of 1.3 lM was injected under the same conditions. Panels (C,D) Kinetic
evaluation of pLG72 binding to immobilized hDAAO. pLG72 diluted in HBS EPþ buffer at concentrations of 0.78, 1.56, and
3.12 lM was injected at a flow rate of 20 lL/min over hDAAO previously immobilized on a CM5 sensor chip (panel C). To
investigate FAD effect on interaction, the same experiment was performed by diluting pLG72 in the presence of different
concentrations of FAD (20 lM in panel D). As negative control a flow cell with previously immobilized human serum albumin
was used. The rate constants for binding (ka) and dissociation (kd) as well as the Kd (¼ kd/ka) values for each single
experimental are reported below each single panel.
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the two model ligands on hDAAO susceptibility as
observed in limited proteolysis experiments on the
hDAAO-pLG72 complex (Fig. 5). The aggregated data
show that benzoate and CPZ affect hDAAO stability
in the cell differently (thus resembling the effects
observed on the pure protein, see previous) but simi-
larly affect the time course for the cellular D/(DþL)
serine concentration ratio due to hDAAO inhibition.
Discussion
Medical evidence supporting the role of NMDA re-
ceptor hypofunction in schizophrenia has prompted
clinical trials of agents that enhance NMDA receptor
functionality.4,21 For example, schizophrenia
patients receiving D-serine (an allosteric activator of
NMDA-type glutamate receptor) together with anti-
psychotics showed significant improvement in their
positive, negative, and cognitive symptoms.22 In
human brain hDAAO is the main perpetrator of oxi-
dation of the gliotransmitter D-serine, for a review
see Refs. 1–3. A number of recent studies focused on
the development of new and effective hDAAO inhibi-
tors as a treatment strategy for schizophrenia by
modulating D-serine concentrations in the brain.10–13
Figure 5. Time course of trypsin digestion of the hDAAO-pLG72 complex (10 lM ¼ 0.4 mg protein/mL of hDAAO and 10 lM
¼ 0.18 mg protein/mL of pLG72) with 10% (w/w) trypsin at 25C in 20 mM Tris-HCl pH 8.5, 150 mM NaCl, 5% glycerol,
0.06% NLS, and 5 mM 2-mercaptoethanol. Panel (A) SDS-PAGE Analysis of samples at different times (see legend to Fig. 2
for details). APOþpLG72 ¼ apoprotein þ pLG72; HOLOþpLG72 ¼ holoenzyme þ pLG72; HOLOþpLG72þBz ¼ holoenzyme
þ pLG72 to which 1 mM benzoate was added; HOLOþpLG72þCPZ ¼ holoenzyme þ pLG72 to which 0.1 mM CPZ was
added. (B) Time course of the intensity of the 40-kDa band (corresponding to the intact hDAAO monomer) as determined by
densitometric analysis of gels such as those reported in panel (A). The intensity of the 40-kDa band of the sample before
adding trypsin (sample in lane Ctrl, panel A) is indicated as 100%. Bars indicate S.E. as determined for at least three
independent experiments.
Table III. Evaluation of the Kinetics of Interaction of Different Ligands as Estimated by Means of SPR Analysis
During pLG72 Binding to Immobilized hDAAO (at 25C, See Legend of Fig. 4 for Details)
Ligand ka (M
1 s1) kd (103 s1) Kd (M) Known value (M)
D-Serine 0.36 4.07 1.1 102 (1.3 102)a
FAD 900 0.17 1.9 107 (8 106)b
CPZ 345 0.55 1.6 106 (5 106)b
Benzoate 92.5 1.10 12 106 (7 106)c
a As determined form stopped-flow kinetic analysis.7
b As determined following the protein fluorescence quenching during apoprotein titration with increasing FAD7 and CPZ9
concentration.
c As determined following absorbance changes at  500 nm following titration of hDAAO with increasing benzoate
concentration.7
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These studies reported on the synthesis and identifi-
cation of new hDAAO inhibitors (mainly aromatic
compounds that bind in the hDAAO active site, for a
structural comparison see Ref. 13) and on their effect
on rat brain D-serine concentration. However, the
investigations did not focus on the effects of these
ligands on hDAAO conformation and stability and on
its interaction with the modulator pLG72 (which is
absent in rats since it is a primate-specific protein).
We here demonstrated that the presence of
ligands profoundly affects hDAAO conformation as
indicated by protein fluorescence, near-UV CD spec-
troscopy, and limited proteolysis studies. Benzoate
and CF3-D-Ala binding protect the holoenzyme from
thermal denaturation and trypsinolysis (Tables I
and II). Both ligands exert a stabilizing effect by
increasing the amount of hDAAO holoenzyme pres-
ent in solution as the result of a 20-fold decrease in
the Kd for FAD binding,
7 mainly due to a similar
decrease in k-1 [Eq. (1)]. Indeed, these two ligands
modify to a different extent the protein conformation
(as made apparent by protein fluorescence): this dif-
ference might be ascribed to the two alternative
positions occupied by Tyr224 side chain in the 3D
structure of hDAAO in complex with benzoate or
with iminoserine (PDB ID 2DU8 and 2E49).1,16 Fur-
thermore, the large change in protein fluorescence of
the apoprotein in the presence of D-serine or CF3-D-
Ala and the thermal stabilization following the bind-
ing of the pseudo-substrate clearly shows that the
Figure 6. Dependence of D-serine and EGFP-hDAAO
concentrations on treatment with benzoate or CPZ in U87
glioblastoma cells stably transfected with pEGFP-hDAAO-
C3 expression vector. (A) Histogram reporting the time
course of the D/(DþL) serine concentration ratio in U87
cells transfected with EGFP-hDAAO and treated without
(control, black bars) or with 10 lM CPZ (white bars) or with
10–100 lM benzoate (gray bars). The values are expressed
as a percentage, taking as 100% the ratio determined for
the control at each time point (0 hours: 2.40 6 0.34; 24
hours: 1.89 6 0.16; 48 hours: 1.93 6 0.18). The change in
D/(DþL) serine ratio was demonstrated to be significant for
CPZ and benzoate treatments at 24 hours (P < 0.001, see
double asterisk) and not significant at 48 hours. (B)
Histogram reporting the time course of the hDAAO
concentration in the same cell samples as in panel A, as
determined by means of Western blot analysis (the bands
detected using anti-GFP antibodies are shown at the top)
and activity assay using the Amplex UltraRed system (see
"Materials and Methods" section). The values are
expressed as a percentage, taking as 100% the amount of
EGFP-hDAAO determined for the control at each time point
(24 hours: 0.059 lg hDAAO/5 x 104 cells and 40 mU
hDAAO/mg protein; 48 hours: 0.058 lg hDAAO/5 x 104
cells and 43 mU hDAAO/mg protein). The change in hDAAO
concentration with respect to the control was demonstrated
to be statistically significant for CPZ-treated samples at 48
hours (P ¼ 0.017, see asterisk) and not statistically
significant for all the remaining samples (P > 0.05). (C)
Same analysis as reported in panel B performed on U87
glioblastoma cells stably expressing EGFP-hDAAO and
transiently transfected with pLG72. The change in hDAAO
concentration with respect to the control is statistically
significant for CPZ-treated samples at 24 and 48 hours (P
< 0.007, see double asterisk) and for the benzoate-treated
sample at 48 hours (P ¼ 0.017, see asterisk). The data are
reported as means 6 S.E.; for each point at least six
independent determinations were performed.
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site for substrate binding is formed in the apoprotein
form of hDAAO. Limited proteolysis studies demon-
strate that FAD binding to the apoprotein quickly
produces a compact protein whose conformation is
similar to that of the hDAAO holoenzyme.15 Suscepti-
bility of hDAAO to trypsinolysis is instead enhanced
by CPZ binding, which also alters the protein fluores-
cence and the near-UV CD signal of the flavoenzyme
differently than in benzoate binding: the binding of
CPZ appears to favor a protein conformation resem-
bling that of the apoprotein form.
Importantly, none of the ligands tested -CPZ,
FAD, benzoate, and D-serine- modified the hDAAO-
pLG72 complex formation, as judged by SPR and gel
permeation analyses although CPZ binding increased
the susceptibility to proteolysis.
Understanding the modulation of hDAAO enzy-
matic activity and stability in vivo (by its cofactor
and/or ligands) is a crucial physiological and patho-
logical issue that has not been clarified yet. At an
estimated in vivo FAD concentration of 5 lM,
hDAAO should be mainly in the apoprotein inactive
form due to the weak cofactor binding. We here dem-
onstrate that the amount of hDAAO holoenzyme is
largely augmented in the presence of the substrate
D-serine (or the pseudo-substrate CF3-D-Ala). All to-
gether, we conclude that hDAAO folding takes place
first, and the cofactor binds to the already folded
apoprotein where the active site is also formed: sub-
strate binding increases FAD-apoprotein interaction
and in turn the holoenzyme active form. Substrate
or benzoate binding also increases hDAAO stability
(Fig. 2), while the stability of the flavoenzyme is neg-
atively affected by the binding of the protein pLG72
or the drug CPZ. In agreement with these results
benzoate and CPZ affect the cellular concentration of
hDAAO differently [Fig. 6(B,C)] although they modu-
late the short-term cellular D-serine concentration
similarly. An increase in the D/(DþL) serine concen-
tration ratio at 24 hours from treatment with both
compounds is apparent (a similar result was also
observed for plasma D-serine levels of rats treated
with the hDAAO inhibitor pyrrole carboxylic acids),11
which is abolished at 48 hours [Fig. 6(A)]. Further-
more, the different effect exerted by benzoate and
CPZ on hDAAO stability and cellular concentration
might affect the in vivo levels of the gliotransmitter
D-serine differently over time. This represents a fur-
ther parameter to take into consideration during the
development of new drugs to treat schizophrenia.
Materials and Methods
Enzymes and activity assay
Recombinant hDAAO and pLG72 proteins were
expressed in E. coli cells and purified as reported.7,8
The EGFP-hDAAO protein form (see later) was also
expressed in E. coli cells by using the pET20 plas-
mid: the recombinant enzyme was purified with a
35% yield and >85% purity as reported in.7 The
final hDAAO preparation was in 20 mM Tris-HCl
buffer, pH 8.0, 100 mM NaCl, 5% glycerol, 5 mM 2-
mercaptoethanol, and 40 lM FAD and diluted in
plain buffer without FAD before use. Apoprotein of
hDAAO was prepared by overnight dialysis of the
holoprotein against 1 M KBr as detailed in.7 The
final pLG72 preparation was stored in 20 mM Tris-
HCl, pH 8.5, 100 mM NaCl, 5% glycerol, and 5 mM
2-mercaptoethanol and contained  0.1% N-lauroyl-
sarcosine (NLS).
Spectral measurements
Flavin and protein fluorescence measurements were
performed in a Jasco FP-750 instrument. The
kinetics of FAD binding to hDAAO apoprotein were
investigated by using a BioLogic SFM-300 stopped-
flow apparatus interfaced to the same Jasco fluorim-
eter.15 Protein emission spectra were taken from 300
to 400 nm (excitation at 280 nm); flavin emission
spectra were recorded from 475 to 600 nm (excita-
tion at 450 nm). Steady-state fluorescence measure-
ments were performed at 0.1 mg/mL protein concen-
tration and corrected for buffer contributions. Fixed
wavelength protein and flavin fluorescence measure-
ments were taken at 335 and 530 nm, respectively.
Temperature ramp experiments were carried out by
using the same instrumentation equipped with a
software-driven Peltier-based temperature controller
(temperature gradient of 0.5C/min); data were ana-
lyzed by means of Jasco software.15 Circular dichro-
ism (CD) spectra were recorded on a J-815 Jasco
spectropolarimeter: cell pathlength was 1 cm for
measurements above 250 nm (0.4 mg protein/mL)
and 0.1 cm for measurements in the 190–250 nm
region (0.1 mg protein/mL). All spectral measure-
ments were carried out in 20 mM Tris-HCl pH 8.5,
150 mM sodium chloride, and 5% glycerol (a differ-
ent buffer as compared to15) and at 15C.
Limited proteolysis
Holo- and apoprotein samples of hDAAO (0.4 mg
protein/mL, corresponding to 10 lM) were incu-
bated at 25C in 20 mM Tris-HCl, pH 8.5, 150 mM
NaCl, 5% glycerol, 0.06% NLS, and 5 mM 2-mercap-
toethanol, with 10% (w/w) trypsin as reported previ-
ously15 and in the presence of different compounds:
pLG72, FAD, benzoate, CF3-D-Ala and CPZ. At vari-
ous times after adding trypsin, aliquots (containing 7
lg of hDAAO) were diluted in sample buffer for SDS-
PAGE, heated at 100C for 3 min, and analyzed elec-
trophoretically. The intensity of the protein bands
was determined by densitometric analysis using the
QuantityOne software (BioRad Lab.). Kinetic data for
protein fragment formation/degradation were fit to a
single or a double exponential decay equation by
using KaleidaGraphTM (Sinergy Software).
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Size-exclusion chromatography
Size-exclusion chromatography was performed at
room temperature on a Superdex 200 column by
means of an A¨kta chromatographic system (Amer-
sham Pharmacia Biotech), using 20 mM Tris-HCl,
pH 8.5, 150 mM sodium chloride, 5% glycerol, 5 mM
2-mercaptoethanol as elution buffer and the follow-
ing compounds added: 40 lM FAD, 0.1 mM CPZ, or
0.1 mM benzoate. The column was calibrated with
suitable standard proteins.
hDAAO-pLG72 complex formation and oligo-
meric state were also determined by gel-permeation
chromatography using the aforementioned buffer to
which 0.06% NLS and 40 lM FAD, 0.1 mM benzoate
or CPZ was added as the elution buffer (the deter-
gent is required because the solubility and the oligo-
meric state of pLG72 strongly depends on the pres-
ence of NLS).9 The area of each peak was estimated
by nonlinear curve fitting of the elution profile using
PeakFit software (Systat Software, Germany); the
error was <10% as estimated using known amounts
of hDAAO as standard protein (5–100 nmoles/run).
The amount of pLG72 and hDAAO present in the
peak corresponding to the protein complex (12.8
mL) was estimated by means of the intensity of their
bands following SDS-PAGE, as obtained using the
program QuantityOne and known amounts of puri-
fied hDAAO and pLG72 as standard.9
SPR analysis
All experiments were performed on a Biacore T100
instrument (GE Healthcare) and materials were pur-
chased from the same supplier if not otherwise
specified. All the analyses were carried out at 25C,
employing 10 mM Hepes, 150 mM NaCl, 3.4 mM
EDTA, 0.05% P20, and 0.01% NLS at pH 7.4 (HBS
EPþ buffer) as running buffer. For protein immobili-
zation, pLG72 or hDAAO diluted at 20 and 25 lg/
mL, respectively, in 10 mM sodium acetate, pH 4.5,
were covalently linked to two flow cells of a CM5
sensor chip through standard amine coupling chem-
istry. The pLG72 sensor chip was less stable and the
coupling procedure was less reproducible than that
for hDAAO, probably because of the low solubility of
pLG72.7,9 For kinetic experiments, hDAAO was
diluted in running buffer at concentrations ranging
from 1 to 10 lM with or without 40 lM FAD (to
evaluate the binding of both the apo- and the holo-
enzyme forms of hDAAO to immobilized pLG72).
Analytes were flushed over the immobilized pLG72
for 120 s at a flow rate of 20 lL/min and the dissoci-
ation phase was followed for 300 s after shifting to
running buffer. Otherwise, pLG72 diluted at concen-
trations ranging from 5 to 0.5 lM in running buffer
was flushed over the immobilized hDAAO sensor
chip for 180 s at a flow rate of 20 lL/min followed by
a dissociation phase of 300 s. Surface regeneration
was achieved with a 30-s pulse of a solution contain-
ing 0.5 M NaCl and 0.5% NLS. The evaluation of
the effect of different compounds on the hDAAO-
pLG72 interaction was performed by flushing pLG72
over a sensor chip with immobilized hDAAO in the
presence of D-serine (50 mM), sodium benzoate (35
lM), CPZ (from 5 to 40 lM), or FAD (from 5 to 40
lM). For each analysis an empty flow cell was used
as a blank reference and a flow cell with immobilized
human serum albumin was used as negative control.
The unrelated acylase and human serum albumin
proteins were employed as negative control analytes.
Kinetic traces were analyzed by Biacore T100
evaluation software 1.1.1 using a 1:1 Langmuir
model for hDAAO-pLG72 interaction. For interac-
tions performed in the presence of small compounds,
kinetic traces were evaluated by means of a model
accounting for heterogeneous analyte interactions.20
Effect of benzoate and CPZ on cellular D-serine
and DAAO concentrations
The cDNA fragment coding for hDAAO was inserted
into the pEGFP-C3 (Clontech Laboratories) vector as
reported in,9 in frame with the gene coding for
EGFP (pEGFP-hDAAO-C3 plasmid). The U87
human glioblastoma cells (ATCC) were transfected
by using the Fugene HD Transfection Reagent
(Roche) as suggested by the supplier. The expression
of the fusion protein was monitored by detecting
GFP fluorescence. U87 Clones stably producing
EGFP-hDAAO were then selected by adding 0.4 mg/
mL G418 to the culture media. The same cells were
then transiently transfected with a plasmid encoding
for pLG72.9 The cellular D- and L-serine levels were
determined using transfected cells treated with 10
or 100 lM benzoate, 10 lM CPZ, or plain buffer for
up to 72 hours. At 0, 24, and 48 hours, 5  105 cells
were suspended in 1 mL of ice-cold 5% trichloroace-
tic acid, sonicated, and centrifuged for 30 min at
13000 rpm. The soluble fraction was extracted and
derivatized with o-phthaldialdehyde/N-acetyl-L-cys-
teine: D- and L-serine were resolved by HPLC chro-
matography on a 5-lm Waters C8 (4.6 x 250 mm)
reversed-phase column.9
The amount of cellular hDAAO on the same
U87 transfected cells was determined by two assays:
a) by SDS-PAGE and Western blot analysis using
anti-hDAAO antibodies raised against its N-terminal
sequence (Davids Biotechnologie) and quantification
by densitometric analysis, see previous and Ref. 9.
The intensity of the band recognized by a goat anti-a-
tubulin antibody (Santa Cruz Biotechnology) was
used as internal control; and b) by DAAO activity
measurements on transfected U87 cell crude extracts
using the Amplex UltraRed assay kit (Invitrogen)
based on the detection of H2O2 by the peroxidase-
mediated oxidation of the fluorogenic dye, as
reported in.9 To measure the entire hDAAO cellular
Caldinelli et al. PROTEIN SCIENCE VOL 19:1500—1512 1511
content, the cell extracts were incubated in the pres-
ence of a large excess of FAD (10 lM) and D-serine
(50 mM); for each sample a control without the sub-
strate D-serine was also analyzed. DAAO activity
was expressed as the difference in fluorescence emis-
sion between sample and control assay mixtures and
reported as specific activity (units/mg protein). Pro-
tein content was determined using the Bradford rea-
gent (Sigma).
The measurements were replicated at least six
times for each condition and statistical analyses
were performed using Kaleidagraph software (Syn-
ergy Software). Variation between groups was eval-
uated by one-way ANOVA, and post hoc significance
tests were performed using a Student’s t test. Signif-
icance was assessed at P < 0.05.
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